Spero Therapeutics to be Delisted from Nasdaq
Ticker: SPRO · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, nasdaq, regulatory
Related Tickers: SPRO
TL;DR
Nasdaq's kicking Spero out, stock's getting delisted Feb 25th. They're fighting it.
AI Summary
Spero Therapeutics, Inc. announced on February 25, 2025, that its common stock will be delisted from the Nasdaq Capital Market. The company received a notice from Nasdaq on February 25, 2025, indicating that its common stock would be delisted due to failure to meet continued listing requirements. Spero Therapeutics intends to appeal this determination.
Why It Matters
This delisting significantly impacts Spero Therapeutics' ability to raise capital and trade its shares, potentially affecting its ongoing research and development efforts.
Risk Assessment
Risk Level: high — Delisting from a major exchange like Nasdaq poses significant financial and operational risks for a company.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where stock is listed
- February 25, 2025 (date) — Date of Nasdaq notice and event
FAQ
What is the primary reason for Spero Therapeutics' delisting from the Nasdaq Capital Market?
Spero Therapeutics received a notice from Nasdaq on February 25, 2025, indicating that its common stock would be delisted due to failure to meet continued listing requirements.
What action does Spero Therapeutics plan to take regarding the delisting notice?
Spero Therapeutics intends to appeal Nasdaq's determination to delist its common stock.
On what date did Spero Therapeutics receive the notice of delisting?
Spero Therapeutics received the notice of delisting on February 25, 2025.
What type of security is being delisted from the Nasdaq Capital Market?
Spero Therapeutics' common stock is being delisted from the Nasdaq Capital Market.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 25, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding Spero Therapeutics, Inc. (SPRO).